ECHELON-2: a phase 3 trial comparing brentuximab vedotin and CHP chemotherapy with standard CHOP in people with T-cell lymphoma that has not yet been treated

This trial is no longer recruiting participants.

Results and 5-year follow-up data for this trial are available.

Purpose of trial

The aim of the trial is to see if a newer drug, ‘brentuximab vedotin’, is safe and effective for people with T-cell lymphoma when used instead of vincristine in the CHOP chemotherapy regimen (combination of drugs).

CHOP chemotherapy (cyclophosphamide, doxorubicin (or hydroxydaunorubicin), vincristine and prednisolone) is the standard treatment for most people with T-cell lymphoma . However, many people don’t respond to treatment or relapse (the lymphoma comes back) soon after treatment.

Brentuximab vedotin is an antibody-drug conjugate. A powerful anti-cancer drug is joined to an antibody. The antibody takes the anti-cancer drug directly to the cancer cells, reducing the effects on normal, healthy cells. Brentuximab vedotin targets a protein called ‘CD30’ on lymphoma cells. You can only enter this trial if your lymphoma cells have CD30.


Participants are randomised by computer to decide which treatment regimen they will have:

  • CHP chemotherapy (no vincristine) and brentuximab vedotin
  • CHOP chemotherapy.

You can’t choose which treatment you have and neither can your doctor. You are told which treatment you are having and given information about it.

Some of the chemotherapy drugs are given intravenously (through a drip into a vein). Others are given orally, as tablets or capsules. Brentuximab vedotin is given intravenously.

Treatment is given in cycles of 3 weeks each. You have treatment on some days, followed by a rest period to allow your body to recover before the next cycle. You have 6–8 cycles of treatment overall.

Who can enter

Your consultant can give you advice on whether this trial might be suitable for you.

Around 450 people are needed for this trial

You may be able to enter if:

  • You have T-cell lymphoma that has CD30.
  • You have not yet had treatment for your lymphoma.
  • Your lymphoma is measurable by the tests used in the trial.
  • You are well enough to look after yourself and up and about more than 50% of your waking hours, even if you are not well enough to work.
  • You are 18 or over.

You will not be able to enter if:

  • Your lymphoma is in your central nervous system (brain and spinal cord).
  • You have any health problems that your doctor thinks might make it unsafe for you to have the trial treatment.
  • You’ve had a previous cancer in the last 3 years, unless it was certain localised cancers.
  • You have skin lymphoma or a lymphoproliferative disorder in your skin.
  • Your medical history includes progressive multifocal leukoencephalopathy (PML).

Further information

More information about this trial is available at